Patents by Inventor Andreas Wilmen
Andreas Wilmen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240034810Abstract: The present invention relates to an isolated antibody or antigen-binding fragment thereof that binds to human A2AP. The isolated antibody or antigen-binding fragment according to the present invention i) cross-reacts with rabbit and/or cynomolgus A2AP, ii) does not inhibit human plasmin activity, and iii) increases plasmin mediated clot lysis in the presence of A2AP.Type: ApplicationFiled: June 6, 2023Publication date: February 1, 2024Inventors: Stefan HEITMEIER, Julia Glunz, Melanie Fischer, Cindy Schulenburg, Hannah Jörissen, Christoph Thiel, Andreas Wilmen, Ernst Weber
-
Publication number: 20240010750Abstract: The present invention relates to an isolated antibody or antigen-binding fragment thereof that binds to human A2AP. The isolated antibody or antigen-binding fragment according to the present invention i) cross-reacts with rabbit and/or cynomolgus A2AP, ii) does not inhibit human plasmin activity, and iii) increases plasmin mediated clot lysis in the presence of A2AP.Type: ApplicationFiled: September 13, 2021Publication date: January 11, 2024Inventors: Stefan HEITMEIER, Julia GLUNZ, Melanie FISCHER, Cindy SCHULENBURG, Hannah JÖRISSEN, Christoph THIEL, Andreas WILMEN, Ernst WEBER
-
Publication number: 20210395390Abstract: The present invention relates to reversal agents, which specifically bind to the anti-FXIa antibody 076D-M007-H04-CDRL3-N110D as described in WO2013/167669, and neutralize the therapeutic activity of this anti-FXIa antibody, as well as to compositions comprising these reversal agents. Methods of obtaining the antibodies or antigen-binding fragments thereof (such as Fab fragments) and nucleic acids encoding the same, are also provided. Furthermore, the invention relates to methods of use of these reversal agents, such as methods for neutralizing the therapeutic activity of the anti-FXIa antibody 076D-M007-H04-CDRL3-N110D, and to related methods as essential part of a general bleeding management.Type: ApplicationFiled: October 31, 2019Publication date: December 23, 2021Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Andreas WILMEN, Ernst WEBER
-
Patent number: 11077187Abstract: Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.Type: GrantFiled: November 15, 2016Date of Patent: August 3, 2021Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Xiao-Yan Zhao, Andreas Wilmen, Christoph Freiberg, Lars Linden, Ji-Yun Kim, Subramanian Yegneswaran, Karin Regnstrom, Ursula Egner, Xinquan Wang
-
Patent number: 11046783Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: GrantFiled: March 4, 2019Date of Patent: June 29, 2021Assignee: Bayer Pharma AktiengesellschaftInventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
-
Publication number: 20210147504Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a Brain Natriuretic Peptide (BNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.Type: ApplicationFiled: April 10, 2019Publication date: May 20, 2021Applicant: Bayer AktiengesellschaftInventors: Damian BROCKSCHNIEDER, Jan TEBBE, Andreas WILMEN, Frank WUNDER
-
Publication number: 20210139555Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.Type: ApplicationFiled: April 10, 2019Publication date: May 13, 2021Applicant: Bayer AktiengesellschaftInventors: Anke MAYER-BARTSCHMID, Damian BROCKSCHNIEDER, Marcel GEERTZ, Simone GREVEN, Lucas Hudson HOFMEISTER, Hannah JÖRISSEN, Christoph MAHLERT, Tobias MARQUARDT, Ilka MATHAR, Thomas MONDRITZKI, Claudia NOACK, Jan TEBBE, Stuart WALSH, Ernst WEBER, Andreas WILMEN, Frank WUNDER
-
Publication number: 20210079056Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a C-Type Natriuretic Peptide (CNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.Type: ApplicationFiled: April 10, 2019Publication date: March 18, 2021Applicant: Bayer AktiengesellschaftInventors: Damian BROCKSCHNIEDER, Lucas Hudson HOFMEISTER, Claudia NOACK, Jan TEBBE, Stuart WALSH, Andreas WILMEN, Frank WUNDER
-
Patent number: 10654941Abstract: The present invention in general relates to novel binding molecules, in particular antibodies and compositions and kits comprising the same. Said binding molecules are capable of binding to human Factor XI and hence envisaged to be particularly useful in inhibiting thrombosis without compromising hemostasis. The binding molecules, compositions and kits provided herein are therefore inter alia intended for treatment of thrombosis-related diseases and conditions. Moreover, polynucleotides encoding the binding molecules of the invention, vectors comprising said polynucleotides and host cells for producing the polynucleotides are provided herein.Type: GrantFiled: September 18, 2017Date of Patent: May 19, 2020Assignees: Bayer Pharma Aktiengesellschaft, ARONORA INC.Inventors: Andreas Wilmen, Anja Buchmüller, Erik Tucker
-
Publication number: 20190284300Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: ApplicationFiled: March 4, 2019Publication date: September 19, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Andreas WILMEN, Julia STRAßBURGER, Frank DITTMER, Michael STRERATH, Anja BUCHMÜLLER, Joanna GRUDZINSKA-GOEBEL, Ricarda FINNERN, Martina SCHÄFER, Christoph GERDES, Hannah JÖRIßEN, Asako ITAKURA, Philberta Y. LEUNG, Erik TUCKER
-
Publication number: 20190225705Abstract: The present invention in general relates to novel binding molecules, in particular antibodies and compositions and kits comprising the same. Said binding molecules are capable of binding to human Factor XI and hence envisaged to be particularly useful in inhibiting thrombosis without compromising hemostasis. The binding molecules, compositions and kits provided herein are therefore inter alia intended for treatment of thrombosis-related diseases and conditions. Moreover, polynucleotides encoding the binding molecules of the invention, vectors comprising said polynucleotides and host cells for producing the polynucleotides are provided herein.Type: ApplicationFiled: September 18, 2017Publication date: July 25, 2019Applicants: Bayer Pharma Aktiengesellschaft, ARONORA INC.Inventors: Andreas WILMEN, Anja BUCHMÜLLER, Erik TUCKER
-
Patent number: 10221247Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: GrantFiled: August 30, 2017Date of Patent: March 5, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
-
Publication number: 20180326053Abstract: Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.Type: ApplicationFiled: November 15, 2016Publication date: November 15, 2018Inventors: Xiao-Yan ZHAO, Andreas WILMEN, Christoph FREIBERG, Lars LINDEN, Ji-Yun KIM, Subramanian YEGNESWARAN, Karin REGNSTROM, Ursula EGNER, Xinquan WANG
-
Patent number: 10040866Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: GrantFiled: August 30, 2017Date of Patent: August 7, 2018Assignee: Bayer Pharma AktiengesellschaftInventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
-
Publication number: 20180112009Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: ApplicationFiled: August 30, 2017Publication date: April 26, 2018Inventors: Andreas WILMEN, Julia STRAßBURGER, Frank DITTMER, Michael STRERATH, Anja BUCHMÜLLER, Joanna GRUDZINSKA-GOEBEL, Ricarda FINNERN, Martina SCHÄFER, Christoph GERDES, Hannah JÖRIßEN, Asako ITAKURA, Philberta Y. LEUNG, Erik TUCKER
-
Publication number: 20180051093Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: ApplicationFiled: August 30, 2017Publication date: February 22, 2018Inventors: Andreas WILMEN, Julia STRAßBURGER, Frank DITTMER, Michael STRERATH, Anja BUCHMÜLLER, Joanna GRUDZINSKA-GOEBEL, Ricarda FINNERN, Martina SCHÄFER, Christoph GERDES, Hannah JÖRIßEN, Asako ITAKURA, Philberta Y. LEUNG, Erik TUCKER
-
Patent number: 9783614Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: GrantFiled: May 8, 2013Date of Patent: October 10, 2017Assignee: Bayer Pharma AktiengesellschaftInventors: Andreas Wilmen, Julia Straβburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jöriβen, Asako Itakura, Philberta Leung, Erik Tucker
-
Patent number: 9777063Abstract: The present invention is directed to the neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody of the invention blocks prolactin receptor-mediated signalling.Type: GrantFiled: April 28, 2016Date of Patent: October 3, 2017Assignee: Bayer Intellectual Property GmbHInventors: Christoph Freiberg, Christiane Otto, Lars Linden, Axel Harrenga, Mark Trautwein, Simone Greven, Andreas Wilmen
-
Patent number: 9649374Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: GrantFiled: November 18, 2010Date of Patent: May 16, 2017Assignee: Bayer Intellectual Property GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
-
Publication number: 20160319029Abstract: The present invention is directed to the neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody of the invention blocks prolactin receptor-mediated signalling.Type: ApplicationFiled: April 28, 2016Publication date: November 3, 2016Inventors: Christoph FREIBERG, Christiane OTTO, Lars LINDEN, Axel HARRENGA, Mark TRAUTWEIN, Simone GREVEN, Andreas WILMEN